The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
Open accessAbstract
Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor that is in clinical trials as a cancer treatment because of its antiproliferative properties. We found that the flavonoid potently inhibited transcription by RNA polymerase II in vitro by blocking the transition into productive elongation, a step controlled by P-TEFb. The ability of P-TEFb to phosphorylate the carboxyl-terminal domain of the large subunit of RNA polymerase II was inhibited by flavopiridol with a K(i) of 3 nm. Interestingly, the drug was not competitive with ATP. P-TEFb composed of Cdk9 and cyclin T1 is a required cellular cofactor for the human immunodeficiency virus (HIV-1) transactivator, Tat. Consistent with its ability to inhibit P-TEFb, flavopiridol blocked Tat transactivation of the viral promoter in vitro. Furthermore, flavopiridol blocked HIV-1 replication in both single-round and viral spread assays with an IC(50) of less than 10 nm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[6] Statistical analysis of enzyme kinetic data
Wallace Cleland, W. (1979) · Methods in Enzymology · doi:10.1016/0076-6879(79)63008-2 · Cited by 1,984
Wei, P., Garber, M. E., Fang, S.-M., Fischer, W. H., & Jones, K. A. (1998) · Cell · doi:10.1016/s0092-8674(00)80939-3 · Cited by 1,249
Yamaguchi, Y., Takagi, T., Wada, T., Yano, K., Furuya, A., Sugimoto, S., Hasegawa, J., & Handa, H. (1999) · Cell · doi:10.1016/s0092-8674(00)80713-8 · Cited by 841
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro
Zhu, Y., Pe’ery, T., Peng, J., Ramanathan, Y., Marshall, N., Marshall, T., Amendt, B., Mathews, M. B., & Price, D. H. (1997) · Genes & Development · doi:10.1101/gad.11.20.2622 · Cited by 696
Self-citationP-TEFb, a Cyclin-Dependent Kinase Controlling Elongation by RNA Polymerase II
Price, D. H. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2629-2634.2000 · Cited by 679
Self-citationControl of RNA Polymerase II Elongation Potential by a Novel Carboxyl-terminal Domain Kinase
Marshall, N. F., Peng, J., Xie, Z., & Price, D. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.43.27176 · Cited by 662
Self-citationCarlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 580
Self-citationMarshall, N. F., & Price, D. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.21.12335 · Cited by 560
Self-citationP-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro
Mancebo, H. S. Y., Lee, G., Flygare, J., Tomassini, J., Luu, P., Zhu, Y., Peng, J., Blau, C., Hazuda, D., Price, D., et al. (1997) · Genes & Development · doi:10.1101/gad.11.20.2633 · Cited by 544
Self-citation
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
c-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Targeting the Cell Cycle: A New Approach to Cancer Therapy
Schwartz, G. K., & Shah, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5594 · Cited by 817
Organization and regulation of gene transcription
Cramer, P. (2019) · Nature · doi:10.1038/s41586-019-1517-4 · Cited by 748
The Long Noncoding RNAs NEAT1 and MALAT1 Bind Active Chromatin Sites
West, J. A., Davis, C. P., Sunwoo, H., Simon, M. D., Sadreyev, R. I., Wang, P. I., Tolstorukov, M. Y., & Kingston, R. E. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.07.012 · Cited by 709
Strategies in the design of antiviral drugs
De Clercq, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd703 · Cited by 652
Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450
Hodek, P., Trefil, P., & Stiborová, M. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(01)00285-x · Cited by 649
Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo
Chao, S.-H., & Price, D. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102306200 · Cited by 621
Self-citationInhibiting eukaryotic transcription: which compound to choose? How to evaluate its activity
Bensaude, O. (2011) · Transcription · doi:10.4161/trns.2.3.16172 · Cited by 574
Pharmacological inhibitors of cyclin-dependent kinases
Knockaert, M., Greengard, P., & Meijer, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02071-0 · Cited by 537
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Olson, C. M., Jiang, B., Erb, M. A., Liang, Y., Doctor, Z. M., Zhang, Z., Zhang, T., Kwiatkowski, N., Boukhali, M., Green, J. L., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2538 · Cited by 552
Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M. (2011) · Genes & Development · doi:10.1101/gad.16962311 · Cited by 522
“Cyclin-dependent kinase 9 (Cdk9), a subunit of positive transcription elongation factor b (P-TEFb) is considered to be the main Ser2 kinase (Chao et al. 2000); however, recent studies suggest that other Ser2 kinases exist in cells (Gomes et al. 2006; Bartkowiak et al. 2010).”
BackgroundSelf-citationXPB, a subunit of TFIIH, is a target of the natural product triptolide
Titov, D. V., Gilman, B., He, Q.-L., Bhat, S., Low, W.-K., Dang, Y., Smeaton, M., Demain, A. L., Miller, P. S., Kugel, J. F., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.522 · Cited by 509
Real-Time Dynamics of RNA Polymerase II Clustering in Live Human Cells
Cisse, I. I., Izeddin, I., Causse, S. Z., Boudarene, L., Senecal, A., Muresan, L., Dugast-Darzacq, C., Hajj, B., Dahan, M., & Darzacq, X. (2013) · Science · doi:10.1126/science.1239053 · Cited by 504
Enhancer transcripts mark active estrogen receptor binding sites
Hah, N., Murakami, S., Nagari, A., Danko, C. G., & Kraus, W. L. (2013) · Genome Research · doi:10.1101/gr.152306.112 · Cited by 476
Born to run: control of transcription elongation by RNA polymerase II
Chen, F. X., Smith, E. R., & Shilatifard, A. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0010-5 · Cited by 447
NF-κB Binds P-TEFb to Stimulate Transcriptional Elongation by RNA Polymerase II
Barboric, M., Nissen, R. M., Kanazawa, S., Jabrane-Ferrat, N., & Peterlin, B. M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00314-8 · Cited by 435
Self-citationByrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., Blum, K. A., Rovin, B., Brooker-McEldowney, M., et al. (2007) · Blood · doi:10.1182/blood-2006-05-020735 · Cited by 390
Devaiah, B. N., Lewis, B. A., Cherman, N., Hewitt, M. C., Albrecht, B. K., Robey, P. G., Ozato, K., Sims, R. J., & Singer, D. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120422109 · Cited by 378
Fujinaga, K., Irwin, D., Huang, Y., Taube, R., Kurosu, T., & Peterlin, B. M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.787-795.2004 · Cited by 371
Self-citationLam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., et al. (2001) · Genome Biology · doi:10.1186/gb-2001-2-10-research0041 · Cited by 370
Self-citationMyeloid cell factor–1 is a critical survival factor for multiple myeloma
Zhang, B., Gojo, I., & Fenton, R. G. (2002) · Blood · doi:10.1182/blood.v99.6.1885 · Cited by 367
Transcription-coupled changes in nuclear mobility of mammalian cis-regulatory elements
Gu, B., Swigut, T., Spencley, A., Bauer, M. R., Chung, M., Meyer, T., & Wysocka, J. (2018) · Science · doi:10.1126/science.aao3136 · Cited by 363
Baumli, S., Lolli, G., Lowe, E. D., Troiani, S., Rusconi, L., Bullock, A. N., Debreczeni, J. É., Knapp, S., & Johnson, L. N. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.121 · Cited by 353
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
RNA helicase DDX21 coordinates transcription and ribosomal RNA processing
Calo, E., Flynn, R. A., Martin, L., Spitale, R. C., Chang, H. Y., & Wysocka, J. (2015) · Nature · doi:10.1038/nature13923 · Cited by 324
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy
Greene, W. C., & Peterlin, B. M. (2002) · Nature Medicine · doi:10.1038/nm0702-673 · Cited by 296
Self-citationThe regulation of protein phosphorylation
Johnson, L. N. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370627 · Cited by 291
Rahmani, M., Davis, E. M., Bauer, C., Dent, P., & Grant, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506551200 · Cited by 288
MacCallum, D. E., Melville, J., Frame, S., Watt, K., Anderson, S., Gianella-Borradori, A., Lane, D. P., & Green, S. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0233 · Cited by 288
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y., & Ashworth, A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0528 · Cited by 287
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
Chen, R., Keating, M. J., Gandhi, V., & Plunkett, W. (2005) · Blood · doi:10.1182/blood-2005-04-1678 · Cited by 259
Protein kinase inhibitors: contributions from structure to clinical compounds
Johnson, L. N. (2009) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004745 · Cited by 256
Henriques, T., Gilchrist, D. A., Nechaev, S., Bern, M., Muse, G. W., Burkholder, A., Fargo, D. C., & Adelman, K. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.10.001 · Cited by 240
Almenara, J., Rosato, R., & Grant, S. (2002) · Leukemia · doi:10.1038/sj.leu.2402535 · Cited by 141
Metadata
- Authors
- Chao, S.-H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., & Price, D. H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-09
- Volume
- 275
- Issue
- 37
- Pages
- 28345-28348
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2147347134
- Cited by
- 455
- References
- 31
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.